Europe May Approve First Whole Plant Cannabis Medicine

A new chapter in the history of medical cannabis may be about to begin in Europe. The German pharmaceutical company Vertanical has presented promising results from a clinical study with VER-01, a medication made from the whole plant extract of Cannabis sativa. If approved, it could become the first whole plant drug authorized on the continent, a symbolic and scientific step towards more natural and comprehensive treatments. This information was confirmed by the Hispanic portal Canamo.Net.

An Extract that Maintains the Plant's Strength

Unlike formulas that isolate only one molecule, VER-01 harnesses the full potential of the plant, including cannabinoids, terpenes, and flavonoids, in a single standardized extract. This is known as the “entourage effect,” where the combination of compounds works synergistically in the body, enhancing therapeutic benefits.

The study, conducted with 820 patients suffering from chronic lower back pain, showed that the use of the medication significantly reduced pain without presenting signs of dependence or withdrawal. The result reinforces the idea that cannabis can be an effective and safer alternative to traditional painkillers, such as opioids.

Path Open for New Health Policies

The expectation is that the German government will evaluate national authorization by 2026. If approved, VER-01 could be recognized in other European Union countries, a move that could accelerate the development of more inclusive and evidence-based health policies.

More than a pharmaceutical advancement, the possible recognition of this medication symbolizes a paradigm shift: the appreciation of the plant in its complete form, respecting its natural complexity and healing potential.

With information from Canamo.net.